Indegene Limited IPO: Check Open/Close Date, IPO Price | Espresso


Indegene Limited IPO opens on May 06. Check IPO Details Issue Date Price

May 02, 2024
Indegene Limited IPO opens on May 06. Check IPO Details Issue Date Price

Indegene Limited is coming out with a public issue to raise Rs 1842 crores from the market.

Below are the details of the Indegene Limited IPO:

  • Issue opens – May 06 (Monday)
  • Issue closes – May 08 (Wednesday)
  • Issue size – Rs 1842 crores
  • Price band – Rs 430 to 452 per equity share
  • Bid lot – 33 shares and in multiples thereof

And here are some details of the company and further details on the IPO.

Company Details:

  • Indegene Limited provide digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Their solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. They achieve this by combining over two decades of healthcare domain expertise and fit-for-purpose technology. Their portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies.
  • They have established client relationships with each of the 20 largest biopharmaceutical companies in the world by revenue for the Financial Year 2023 (Source: Everest Report), having earned more than 69.00% of their total revenue from operations for each of the nine months ended December 31, 2023 and 2022 and the Financial Years 2023, 2022 and 2021 from these 20 customers. As of December 31, 2023, they had a total of 65 active clients.
  • Positioned at the intersection of healthcare and technology, their solutions span across different stages of the commercialization lifecycle of drugs and medical devices. Their Enterprise Commercial Solutions and their Omnichannel Activation solutions cater to the commercial functions of life sciences companies while their Enterprise Medical Solutions and Enterprise Clinical Solutions cater to their medical and R&D functions.
  • As of December 31, 2023, they had 65 active clients. They deliver solutions to them from their operation hubs located across North America, Europe and Asia. They have internally developed artificial intelligence (“AI”) and machine learning (“ML”) based proprietary platforms, which allow them to offer their solutions across the globe at scale. Their delivery model allows them to operate where their clients are located. As of December 31, 2023, they had 5,181 full-time employees across 10 countries, of which 4,510 employees were delivery employees (i.e., employees who do not belong to corporate and support functions). As of December 31, 2023, 20.49% of their delivery employees had healthcare-related educational backgrounds.

Issue Size:

Rs. 1842 crores

Employee Reservation: 

2,96,208 Equity Shares aggregating up to Rs.12.50/- crs.

Employee Discount:

Rs. 30 Per Share

Issue break-up:

  • QIB – 50% of the net offer – Rs 914.63 crores
  • NIB – 15% of the net offer – Rs 274.39 crores
  • RET – 35% of the net offer – Rs 640.24 crores




Link Intime India Pvt Ltd


All Retail & NII bidders' (bids up to Rs. 5,00,000) applications through brokers are compulsorily in UPI Mode.


Application made using third-party UPI or ASBA Bank A/c are liable to be rejected.

The UPI Mandate acceptance time for Retail and NII Bidders (bids up to Rs 5,00,000) shall expire at 5 PM on the closing day of the IPO i.e. Wednesday, May 08, 2024

Not an Espresso customer, but still want to apply for the IPO? Become an Espresso customer in just 15 mins* by tapping here and take it from there! (* T&C apply)

Team Espresso
by Team Espresso

We care that you succeed

Bringing readers the latest happenings from the world of Trading and Investments specifically and Finance in general.